Medicare to cover expensive 癌 独房 therapies
By Deena Beasley
Aug 7 (Reuters) - The U.S. 中心s for Medicare and Medicaid Services (CMS) on Wednesday said it has 完結するd a 決定／判定勝ち（する） to cover expensive 癌 独房 therapies sold by Gilead Sciences Inc and Novartis AG.
CMS, which runs Medicare - the 連邦の 政府's health 計画（する） for Americans 65 and older - said it will cover the U.S. Food and 麻薬 行政-認可するd therapies when 供給するd in healthcare 施設s that have programs in place to 跡をつける 患者 結果s.
The 全国的な 決定／判定勝ち（する） （疑いを）晴らすs up "a lot of 混乱" about ニュース報道 and will help 患者s get 接近 to the novel therapies, known as CAR-T, CMS 行政官／管理者 Seema Verma said during a 会議／協議会 call with reporters on Wednesday.
The 決定／判定勝ち（する） follows the 機関's finalization last week of a 提案 to raise its 最大限 CAR-T 支払い（額） to 65% of 概算の costs from 50%. Some hospitals will also be 適格の for supplemental 支払い（額）s in 確かな 事例／患者s.
Both Gilead's Yescarta and Novartis' Kymriah were 認可するd in 2017 for 確かな 肉親，親類d of lymphoma and 白血病. But 政府 and 私的な health 計画（する）s have 妨げるd at their high price of at least $373,000 for a one-time 治療 before hospital costs, which can bring the 法案 for a 選び出す／独身 患者 to over a million dollars.
More than half of lymphoma 患者s 適格の for CAR-T therapy are 概算の to be covered by Medicare.
The 機関 said it will also cover the CAR-Ts for uses not 認可するd in their labels, as long as they are recommended by CMS-認可するd 医療の 指導基準s.
The novel 治療s 除去する a type of 免疫の system 独房s from each individual 患者 and re-engineer them to better fight 確かな 血 癌s, keeping nearly 40% of 患者s alive for more than two years, によれば some 熟考する／考慮するs. (報告（する）／憶測ing by Deena Beasley in Los Angeles and Ankur Banerjee in Bengaluru; Editing by 法案 Berkrot)
